The Dow Ends the Week at Record Highs; Why Did Merck and Pfizer Fall the Most?

Record highs are worthy of celebrating, but the Dow's pharma stocks are lagging badly.

May 10, 2014 at 5:04PM

Over the past week, the Dow Jones Industrials (DJINDICES:^DJI) gained 70 points, hitting a new high on Friday to mark the second all-time record close in 2014 for the Dow. As geopolitical risk from Russia and Ukraine took an important step toward potential de-escalation and as signs of economic stability and growth continued to appear, the stock market reacted favorably. But for Merck (NYSE:MRK) and Pfizer (NYSE:PFE), the Dow's gains have been irrelevant, with both stocks dropping around 5% in just the past week.

Blood Sample
Source: U.S. Navy, Wikimedia Commons.

The pharma blues
Both Merck and Pfizer are going through some major transformational events, and despite what's happening to their respective share prices, not all of those events are inherently negative in tone. Merck announced Tuesday that it would sell off its consumer-care business to Germany's Bayer for $14.2 billion, addressing at least some of the concerns of investors who argued that Merck needed to make more moves toward restructuring its massive operations in order to keep up with rival Pfizer. For its part, Pfizer has more aggressively made corporate shifts, with the spinoff of its animal-health business being just one of the ways Pfizer has tried to streamline its operations.

One question that came up this week is whether Merck might also try to make another similarly sized massive business sale. As Fool analysts David Williamson and Michael Douglass discussed Monday, Merck is rumored to be trying to sell its established-products unit, which includes drugs that have come off-patent, for as much as $15 billion. That could give Merck a $30 billion war chest to use to improve its competitive position.


Yet investors might justifiably be worried about what comes next once Merck has all that cash. Pfizer marks one example of what can happen in today's pharma M&A environment, with its massive attempt to buy out AstraZeneca setting price tags well in excess of $100 billion. Yet even a 12-figure buyout isn't enough for Astra management, who argue that the British drug company has plenty of prospects as an independent company. Pfizer has already had to up its bid once, and the fear that having a lot of available cash -- or a well-valued stock to use as currency -- will prove too much to resist even if it requires paying premium prices. Especially if the Pfizer deal goes through, the temptation for Merck to keep pace with a big acquisition of its own might well prove overwhelming -- and disastrous for shareholders in the long run.

The big takeaway you should draw from Pfizer's and Merck's declines this week is that the pharmaceutical industry is getting more dangerous, and companies have to take bigger risks in order to reap bigger rewards. For those who see Merck and Pfizer merely as solid dividend stocks, that's a wake-up call that should make you think twice about your thesis for owning their shares.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next-trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Caplinger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers